Trianni licenses humanized model platform to MacroGenics for oncology research

By Maggie Lynch

- Last updated on GMT

(Image: Getty/JacobStudio)
(Image: Getty/JacobStudio)

Related tags models Model organism Mouse models Research and development R&D Immune response License

Trianni to provide MacroGenics with humanized mouse model platform for its mAb therapeutics research.

MacroGenics has licensed The Trianni Mouse, a transgenic mouse R&D platform for the discovery of fully-human monoclonal antibodies (mAb). The agreement with Trianni will support MacroGenics’ discovery programs for mAb therapeutics used in oncology.

Ezio Bonvini, chief scientific officer of MacroGenics, said in a press release, that the company can use the mouse for its molecules that are based on its Fc optimization and multi-specific DART and TRIDENT platforms. Applying antibodies into these molecules MacroGenics can accelerate its candidate development processes.

Trianni’s platform combines human antibody repertoire with wild-type mouse immune responses to target antigens, according to the company.

Trianni did not respond to a request for comment.

In October of 2017, Juno Therapeutics also signed a licensing agreement with Trianni for its mAb platform. Juno used the mouse model to identify full-human binders for conversion to chimeric antigen receptors as part of the company’s engineered T cell programs.

Juno stated at the time that it was to use the program to establish “next-generation CAR-T cells.”

Humanized mouse model systems are not new, but technology is emerging that could improve their use. Recently, scientists at CytoReason developed a mouse to human​ model. The model is a machine-learning platform for human immune system cell-level simulation. 

Related news

Show more

Related products

show more

Related suppliers